Exact Mass: 633.3546

Exact Mass Matches: 633.3546

Found 141 metabolites which its exact mass value is equals to given mass value 633.3546, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

PC(2:0/PGE2)

(2-{[(2R)-3-(acetyloxy)-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3278)


PC(2:0/PGE2) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/PGE2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(PGE2/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3278)


PC(PGE2/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(PGE2/2:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(2:0/PGD2)

(2-{[(2R)-3-(acetyloxy)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3278)


PC(2:0/PGD2) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/PGD2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(PGD2/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3278)


PC(PGD2/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(PGD2/2:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

(2-{[(2R)-3-(acetyloxy)-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3278)


PC(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3278)


PC(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

Sativanine F|sativanine-F

Sativanine F|sativanine-F

C34H43N5O7 (633.3162)


   

(?)-(A-b)-14alpha-benzoyloxy-N-ethyl-3alpha,10beta,13beta,15alpha-tetrahydroxy-1alpha,6alpha,8beta,16beta,18-pentamethoxyaconitane

(?)-(A-b)-14alpha-benzoyloxy-N-ethyl-3alpha,10beta,13beta,15alpha-tetrahydroxy-1alpha,6alpha,8beta,16beta,18-pentamethoxyaconitane

C33H47NO11 (633.3149)


   

cyclo-(Pro-Gly-Leu-Val-Pro-Ile-Gly)|gypsophin E

cyclo-(Pro-Gly-Leu-Val-Pro-Ile-Gly)|gypsophin E

C31H51N7O7 (633.385)


   
   
   

(3beta,4S,7alpha,9R,14alpha,15alpha,16beta)-3-acetoxy-4,9-epoxy-15-{[(2Z)-2-methylbut-2-enoyl]oxy}cevane-4,7,14,16,20-pentol

(3beta,4S,7alpha,9R,14alpha,15alpha,16beta)-3-acetoxy-4,9-epoxy-15-{[(2Z)-2-methylbut-2-enoyl]oxy}cevane-4,7,14,16,20-pentol

C34H51NO10 (633.3513)


   

Val Tyr Pro Glu Leu

Val Tyr Pro Glu Leu

C31H47N5O9 (633.3374)


   

Phe Arg Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C27H47N13O5 (633.3823)


   

Arg Phe Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C27H47N13O5 (633.3823)


   

Arg Arg Phe Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C27H47N13O5 (633.3823)


   

Arg Arg Arg Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C27H47N13O5 (633.3823)


   

PKOHA-PC

1-hexadecanoyl-2-(4,7-dioxo-5E-heptenoyl)-sn-glycero-3-phosphocholine

C31H56NO10P (633.3642)


   

OON-PE

1-(9Z-octadecenoyl)-2-(9-oxo-nonanoyl)-sn-glycero-3-phosphoethanolamine

C32H60NO9P (633.4005)


   

OKHdiA-PE

1-(9Z-octadecenoyl)-2-(4-oxo-6-carboxy-5E-hexenoyl)-sn-glycero-3-phosphoethanolamine

C30H52NO11P (633.3278)


   

OHOOA-PE

1-(9Z-octadecenoyl)-2-(5-hydroxy-8-oxo-6E-octenoyl)-sn-glycero-3-phosphoethanolamine

C31H56NO10P (633.3642)


   

TRAP-5 amide trifluoroacetate salt

TRAP-5 amide trifluoroacetate salt

C30H51N9O6 (633.3962)


   

Inhibitor bea388

Inhibitor bea388

C35H43N3O8 (633.305)


   

soyasapogenol B 3-O-beta-glucuronate

soyasapogenol B 3-O-beta-glucuronate

C36H57O9- (633.4002)


A monocarboxylic acid anion that results from the removal of a proton from the carboxy group of soyasapogenol B 3-O-beta-glucuronide.

   

3-Glc-hederagenin

3-Glc-hederagenin

C36H57O9- (633.4002)


   
   
   
   
   

PC(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PC(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C30H52NO11P (633.3278)


   

PC(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0)

PC(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0)

C30H52NO11P (633.3278)


   

2-amino-3-[[3-[(15Z,18Z)-hexacosa-15,18-dienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-[(15Z,18Z)-hexacosa-15,18-dienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C32H60NO9P (633.4005)


   

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-6,9,12,15,18,21,24,27-octaenoate

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-6,9,12,15,18,21,24,27-octaenoate

C35H56NO7P (633.3794)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

2-amino-3-[[3-decoxy-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-decoxy-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C32H60NO9P (633.4005)


   

2-amino-3-[hydroxy-[3-[(Z)-tridec-9-enoxy]-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

2-amino-3-[hydroxy-[3-[(Z)-tridec-9-enoxy]-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

C32H60NO9P (633.4005)


   

2-amino-3-[[2-decanoyloxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[2-decanoyloxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid

C32H60NO9P (633.4005)


   

2-amino-3-[hydroxy-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxypropanoic acid

2-amino-3-[hydroxy-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxypropanoic acid

C31H56NO10P (633.3642)


   

2-amino-3-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3642)


   

2-amino-3-[[3-heptanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-heptanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3642)


   

2-amino-3-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3642)


   

2-amino-3-[[3-hexanoyloxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-hexanoyloxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3642)


   

2-amino-3-[[3-butanoyloxy-2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-butanoyloxy-2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3642)


   

2-amino-3-[[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3642)


   

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadeca-4,8,12-trien-2-yl]propanamide

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadeca-4,8,12-trien-2-yl]propanamide

C30H51NO13 (633.336)


   

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradeca-4,8,12-trien-2-yl]butanamide

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradeca-4,8,12-trien-2-yl]butanamide

C30H51NO13 (633.336)


   

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhexadeca-4,8,12-trien-2-yl]acetamide

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhexadeca-4,8,12-trien-2-yl]acetamide

C30H51NO13 (633.336)


   
   
   

PC O-16:0/8:3;O2

PC O-16:0/8:3;O2

C32H60NO9P (633.4005)


   
   
   
   

PC P-16:0/8:2;O2

PC P-16:0/8:2;O2

C32H60NO9P (633.4005)


   
   

PC P-16:1/8:1;O2

PC P-16:1/8:1;O2

C32H60NO9P (633.4005)


   

PC P-20:1/4:1;O2

PC P-20:1/4:1;O2

C32H60NO9P (633.4005)


   
   
   
   
   
   
   
   
   
   
   
   

PE O-20:0/7:3;O2

PE O-20:0/7:3;O2

C32H60NO9P (633.4005)


   
   
   
   
   

PE P-18:1/9:1;O2

PE P-18:1/9:1;O2

C32H60NO9P (633.4005)


   

PE P-20:0/7:2;O2

PE P-20:0/7:2;O2

C32H60NO9P (633.4005)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

PS P-16:1/10:0 or PS O-16:2/10:0

PS P-16:1/10:0 or PS O-16:2/10:0

C32H60NO9P (633.4005)


   
   
   
   
   

PS P-22:0/4:1 or PS O-22:1/4:1

PS P-22:0/4:1 or PS O-22:1/4:1

C32H60NO9P (633.4005)


   
   

PS P-22:1/4:0 or PS O-22:2/4:0

PS P-22:1/4:0 or PS O-22:2/4:0

C32H60NO9P (633.4005)


   
   

PS P-26:1 or PS O-26:2

PS P-26:1 or PS O-26:2

C32H60NO9P (633.4005)


   
   
   
   
   

ST 22:0;O8;HexNAc

ST 22:0;O8;HexNAc

C30H51NO13 (633.336)


   

ST 25:5;O6;HexNAc

ST 25:5;O6;HexNAc

C33H47NO11 (633.3149)


   

ST 26:4;O5;HexNAc

ST 26:4;O5;HexNAc

C34H51NO10 (633.3513)


   

ST 27:3;O4;HexNAc

ST 27:3;O4;HexNAc

C35H55NO9 (633.3877)


   
   

3-O-β-abritetraosyl soyasapogenol B

NA

C36H57O9- (633.4002)


{"Ingredient_id": "HBIN009131","Ingredient_name": "3-O-\u03b2-abritetraosyl soyasapogenol B","Alias": "NA","Ingredient_formula": "C36H57O9-","Ingredient_Smile": "CC1(CC2C3=CCC4C5(CCC(C(C5CCC4(C3(CCC2(C(C1)O)C)C)C)(C)CO)OC6C(C(C(C(O6)C(=O)[O-])O)O)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "36590","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

aconifine; 8-o-de-ac,8-et ether,n-de-et,n-me

NA

C33H47NO11 (633.3149)


{"Ingredient_id": "HBIN014570","Ingredient_name": "aconifine; 8-o-de-ac,8-et ether,n-de-et,n-me","Alias": "NA","Ingredient_formula": "C33H47NO11","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7200","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1s,2r,3r,4r,5r,6s,7s,8r,9r,10r,13r,14r,16s,17s,18r)-11-ethyl-5,7,8,14-tetrahydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate

(1s,2r,3r,4r,5r,6s,7s,8r,9r,10r,13r,14r,16s,17s,18r)-11-ethyl-5,7,8,14-tetrahydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate

C33H47NO11 (633.3149)


   

3-[(13s)-5,6,9,12,15,16-hexahydroxy-2-oxo-7-[(2e,4e,6e)-pentadeca-2,4,6-trien-1-yl]-3h,3ah,6h,7h,10h,13h,16h,16ah-furo[3,2-l]1,4,7,11-tetraazacyclopentadecan-13-yl]propanimidic acid

3-[(13s)-5,6,9,12,15,16-hexahydroxy-2-oxo-7-[(2e,4e,6e)-pentadeca-2,4,6-trien-1-yl]-3h,3ah,6h,7h,10h,13h,16h,16ah-furo[3,2-l]1,4,7,11-tetraazacyclopentadecan-13-yl]propanimidic acid

C31H47N5O9 (633.3374)


   

(1s,8r,11s,18r,21s,24r)-19,22-dihydroxy-24-isopropyl-10,11-dimethyl-21-(2-methylpropyl)-3,4,10,13,14,20,23,26,27-nonaazatetracyclo[24.4.0.0³,⁸.0¹³,¹⁸]triaconta-19,22-diene-2,9,12,25-tetrone

(1s,8r,11s,18r,21s,24r)-19,22-dihydroxy-24-isopropyl-10,11-dimethyl-21-(2-methylpropyl)-3,4,10,13,14,20,23,26,27-nonaazatetracyclo[24.4.0.0³,⁸.0¹³,¹⁸]triaconta-19,22-diene-2,9,12,25-tetrone

C30H51N9O6 (633.3962)


   

19,22-dihydroxy-24-isopropyl-10,11-dimethyl-21-(2-methylpropyl)-3,4,10,13,14,20,23,26,27-nonaazatetracyclo[24.4.0.0³,⁸.0¹³,¹⁸]triaconta-19,22-diene-2,9,12,25-tetrone

19,22-dihydroxy-24-isopropyl-10,11-dimethyl-21-(2-methylpropyl)-3,4,10,13,14,20,23,26,27-nonaazatetracyclo[24.4.0.0³,⁸.0¹³,¹⁸]triaconta-19,22-diene-2,9,12,25-tetrone

C30H51N9O6 (633.3962)


   

n-{1-[(13z)-10-benzyl-8,11-dihydroxy-16-methoxy-2-oxa-6,9,12-triazatricyclo[13.3.1.0³,⁷]nonadeca-1(18),8,11,13,15(19),16-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl}-2-[(hydroxymethylidene)amino]-3-methylbutanimidic acid

n-{1-[(13z)-10-benzyl-8,11-dihydroxy-16-methoxy-2-oxa-6,9,12-triazatricyclo[13.3.1.0³,⁷]nonadeca-1(18),8,11,13,15(19),16-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl}-2-[(hydroxymethylidene)amino]-3-methylbutanimidic acid

C34H43N5O7 (633.3162)


   

6,9-dibenzyl-5,8,11,14-tetrahydroxy-15-isopropyl-1-methyl-3,12-bis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-4,7,10,13-tetraen-2-one

6,9-dibenzyl-5,8,11,14-tetrahydroxy-15-isopropyl-1-methyl-3,12-bis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-4,7,10,13-tetraen-2-one

C36H51N5O5 (633.389)


   

(3r,6r,9r,12r,15r)-6,9-dibenzyl-5,8,11,14-tetrahydroxy-15-isopropyl-1-methyl-3,12-bis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-4,7,10,13-tetraen-2-one

(3r,6r,9r,12r,15r)-6,9-dibenzyl-5,8,11,14-tetrahydroxy-15-isopropyl-1-methyl-3,12-bis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-4,7,10,13-tetraen-2-one

C36H51N5O5 (633.389)


   

(3r,6s,9s,12s,17as)-9-benzyl-1,4,10-trihydroxy-6-[(4-hydroxyphenyl)methyl]-3-isopropyl-8-methyl-12-(2-methylpropyl)-3h,6h,9h,12h,15h,16h,17h,17ah-pyrrolo[1,2-a]1,4,7,10,13-pentaazacyclopentadecane-7,13-dione

(3r,6s,9s,12s,17as)-9-benzyl-1,4,10-trihydroxy-6-[(4-hydroxyphenyl)methyl]-3-isopropyl-8-methyl-12-(2-methylpropyl)-3h,6h,9h,12h,15h,16h,17h,17ah-pyrrolo[1,2-a]1,4,7,10,13-pentaazacyclopentadecane-7,13-dione

C35H47N5O6 (633.3526)